This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Blue Bird (BLBD) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Blue Bird (BLBD) closed at $43.33, marking a -3.26% move from the previous day.
Why Blue Bird (BLBD) Dipped More Than Broader Market Today
by Zacks Equity Research
Blue Bird (BLBD) closed at $45.26 in the latest trading session, marking a -1.86% move from the prior day.
Brokers Suggest Investing in Blue Bird (BLBD): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Blue Bird (BLBD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Blue Bird (BLBD) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Blue Bird (BLBD) stood at $43.95, denoting a +2.47% move from the preceding trading day.
Blue Bird (BLBD) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the latest trading session, Blue Bird (BLBD) closed at $45.64, marking a +1.22% move from the previous day.
Wall Street Bulls Look Optimistic About Blue Bird (BLBD): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Blue Bird (BLBD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Blue Bird (BLBD) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Blue Bird (BLBD) stood at $44.2, denoting a +2.41% move from the preceding trading day.
Blue Bird (BLBD) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Blue Bird (BLBD) settling at $42.88, representing a +2.17% change from its previous close.
Why Blue Bird (BLBD) Dipped More Than Broader Market Today
by Zacks Equity Research
Blue Bird (BLBD) reached $40.80 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.
Wall Street Analysts Think Blue Bird (BLBD) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Blue Bird (BLBD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Blue Bird (BLBD) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Blue Bird (BLBD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Blue Bird (BLBD) Q2 Earnings Match Estimates
by Zacks Equity Research
Blue Bird (BLBD) delivered earnings and revenue surprises of 0% and 7.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Blue Bird Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
The Zacks Consensus Estimate for BLBD's fiscal second-quarter EPS and revenues is pegged at 96 cents and $390 million, respectively.
Lucid Group (LCID) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lucid Group (LCID) delivered earnings and revenue surprises of -4.35% and 0.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Blue Bird (BLBD) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Blue Bird (BLBD) concluded the recent trading session at $35.36, signifying a -0.69% move from its prior day's close.
Wall Street Analysts See Blue Bird (BLBD) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Blue Bird (BLBD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Blue Bird (BLBD) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Blue Bird (BLBD) settling at $34.50, representing a -1.6% change from its previous close.
Blue Bird (BLBD) Stock Moves -1.38%: What You Should Know
by Zacks Equity Research
The latest trading day saw Blue Bird (BLBD) settling at $33.24, representing a -1.38% change from its previous close.
Blue Bird (BLBD) Stock Moves -0.77%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Blue Bird (BLBD) stood at $33.65, denoting a -0.77% change from the preceding trading day.
Is It Worth Investing in Blue Bird (BLBD) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Blue Bird (BLBD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks Industry Outlook Highlights Tesla, General Motors and Blue Bird
by Zacks Equity Research
Tesla, General Motors and Blue Bird have been highlighted in this Industry Outlook article.
3 Domestic Auto Stocks to Watch Amid Growing Economic Uncertainty
by Lavina Shahu
Domestic auto players like TSLA, GM and BLBD are expected to withstand the industry headwinds better.
Why the Market Dipped But Blue Bird (BLBD) Gained Today
by Zacks Equity Research
Blue Bird (BLBD) concluded the recent trading session at $32.43, signifying a +1.6% move from its prior day's close.
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos
by Zacks Equity Research
Context Therapeutics, Blue Bird, Dycom Industries and Leidos are part of the Zacks Screen of the Week article.
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Context Therapeutics Inc. (CNTX), Blue Bird (BLBD), Dycom Industries (DY) and Leidos (LDOS).